Download Image
    
Share
  
Post
YKYY017 for COVID-19
1 study with 239 patients
Hospital Icon Control
Hospital Icon YKYY017 Serious Outcome Risk
Significantly lower risk for recovery.
COVID-19 YKYY017 studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -150% Viral clearance 13% RCTs -150% Early -150% FavorsYKYY017 Favorscontrol
Recent:
Wang.
Aug 7
 Wang et al., Nature Communication, doi:0.1038/s41467-025-62214-x The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial
31% improved recovery (p=0.003) and 13% improved viral load (p=0.08). RCT 239 mostly mild COVID-19 outpatients showing the primary endpoint of viral load reduction at day 4 was not met with inhaled peptide YKYY017. The 20mg group showed significantly faster time to recovery. The study population was low-ris..